Gen-Probe (GPRO) Upgraded to Outperform at Robert W. Baird

Gen-Probe (GPRO) has been upgraded today by the securities research analysts at investment firm Robert W. Baird which raised Gen-Probe from a “neutral” rating to “outperform.”  Baird, however, cut their performance outlook for GPRO  and adjusted its price target from $82 to $75 dollars.  Baird noted that their decreased price target is partly based on potential suitors of Gen-Probe (LIFE, Novartis and TMO) having walked away into the sunset.  Still, Baird upgrades GPRO based on what they find is a good risk, reward opportunity in the company.

GPRO continues to slide down the wall of the market after having broken beneath support of the $64.65 price level on July 14th, 2011, and there has been no cure in sight yet which will slow bearish momentum.  There has been regular speculation that Gen-Probe will be picked up by another company, only for those assumptions to be proven false.  Today is another dose of that reality.

Gen-Probe is slated to release their next earnings report on July 28th, 2011, and the current consensus EPS estimate is expected to be 49 cents.  Gen-Probe’s last earnings report was released on April 28th, 2011, and announced EPS of 54 cents with revenue totaling $143 million dollars which was up 5.6% year to year.  GPRO is currently trading below its 50 & 200-day moving averages and 2011 is an up year for the company.

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  The company has market capitalization of $2,992,060,220 and 47,942,000 shares outstanding.  GPRO has a 52-week high of $86.96 with the low being an even $42 dollars.

Latest News

FleetCor Technologies  Earns “Hold” Rating from Mizuho
FleetCor Technologies Earns “Hold” Rating from Mizuho
Morningstar, Inc.  Insider Joseph D. Mansueto Sells 16,547 Shares of Stock
Morningstar, Inc. Insider Joseph D. Mansueto Sells 16,547 Shares of Stock
Analysts’ Weekly Ratings Changes for Alder Biopharmaceuticals
Analysts’ Weekly Ratings Changes for Alder Biopharmaceuticals
Gold Bits Coin Market Capitalization Tops $21.60 Million
Gold Bits Coin Market Capitalization Tops $21.60 Million
FlorinCoin  Market Cap Reaches $7.63 Million
FlorinCoin Market Cap Reaches $7.63 Million
Enrique A. Conterno Sells 25,000 Shares of Eli Lilly And Co  Stock
Enrique A. Conterno Sells 25,000 Shares of Eli Lilly And Co Stock


© 2006-2019 Ticker Report